You searched for: immuunvastused (Estniska - Engelska)

immuunvastused erirühmadel
immune responses in special populations

immuunvastused pärast subkutaanset manustamist
immune responses after subcutaneous administration

immuunvastused lastel vanuses 12...14 elukuud
immune responses in toddlers aged 12-14 months

immuunvastused imikutel pärast esmast kaheannuselist vaktsineerimist
immune responses following a two-dose primary infant series

ixiaro esilekutsutud immuunvastused on esitatud tabelis 10.
the immune responses elicited by ixiaro are presented in table 10.

immuunvastused 12 kuu vanuselt manustatud revaktsineerimisannusele jäid mõjutamata.
responses to the booster dose administered at 12 months were unaffected.

need kliinilised uuringud näitasid, et immuunvastused jäid mõjustamata.
in these clinical studies, it was demonstrated that the immune responses were unaffected.

revaktsineerimise immuunvastused imikutel pärast esmast kahe- ja kolmeannuselist vaktsineerimist
booster responses following two-dose and three-dose primary infant series

pärast teist annust olid immuunvastused võrreldavad vastustega pärast esimest annust.
after the second dose immune responses were comparable to those after the first dose.

ei ole tõenäoline, et immuunvastused somatropin biopartners’ile on kliiniliselt olulised.
it is unlikely that the antibody responses to treatment with somatropin biopartners are of clinical relevance.

immuunvastused vaxelis’ele olid nendel imikutel üldiselt sarnased üldise uuringupopulatsiooni omadele.
the immune responses to vaxelis in these infants were generally similar to those of the overall study population.

kliinilised uuringud näitasid, et manustatud vaktsiinide suhtes tekkinud immuunvastused ja vaktsiinide ohutusprofiil ei muutunud.
clinical studies demonstrated that the immune responses and the safety profiles of the administered vaccines were unaffected.

gmt-des mõõdetud gardasil 9 immuunvastused olid samaväärsed immuunvastustega gardasilile (tabel 3).
immune responses, measured by gmt, for gardasil 9 were non-inferior to immune responses for gardasil (table 3).

pärast prevenar 13 teise ja kolmanda annuse manustamist olid immuunvastused sarnased või suuremad kui pärast esimese annuse manustamist.
after the second and third dose of prevenar 13, immune responses were similar or higher than those after the first dose.

hpv nakatab ainult inimesi, kuid loomkatsed analoogsete papilloomiviirustega viitavad, et l1 vlp vaktsiinide efektiivsust vahendavad humoraalsed immuunvastused.
hpv only infects humans, but animal studies with analogous papillomaviruses suggest that the efficacy of li vlp vaccines is mediated by the development of a humoral immune response.

revaktsineerimise järgsed immuunvastused selles vanuserühmas olid üldjuhul sarnased nendega, mida täheldati alla 6 kuu vanuses kolm annust saanud imikute revaktsineerimise järgselt.
the immune responses after the booster dose in this age group were generally similar to those observed after the booster dose in infants who had been primed with 3 doses below 6 months of age.

võrdluskemikaalid valideerimisel kasutamiseks välja valitud kemikaalid, mille esilekutsutavad immuunvastused in vitro või in vivo võrdlussüsteemis või huvipakkuva loomaliigi puhul on juba teada.
reference chemicals chemicals selected for use in the validation process, for which responses in the in vitro or in vivo reference test system or the species of interest are already known.

gardasil 9 immuunvastused 2-annuselise skeemi kasutamisel 9…14-aastastel (kaasa arvatud) isikutel
immune responses to gardasil 9 using a 2-dose schedule in individuals 9 through 14 years of age

Üldiselt täheldati erinevate skeemide puhul võrreldavaid immuunvastuseid, kuigi 2-4-6 kuu skeemi puhul olid immuunvastused mõnevõrra kõrgemad.
in general, comparable vaccine responses were observed for the different schedules, although somewhat higher immune responses were noted for the 2-4-6 month schedule.

pärast revaktsineerimisannust väikelastel tekkinud immuunvastused näitasid aga piisavat esmast immuniseerimist, kuna nii imikuna tehtud kolme- kui ka kaheannuselised vaktsineerimised andsid kõigi 7 serotüübi puhul võrreldavad immuunvastused.
however, antibody responses to booster doses in toddlers following two-dose or three-dose infant series were comparable for all 7 vaccine serotypes and indicated that both infant regimens had elicited adequate priming.